{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:36:39Z","timestamp":1787772999340,"version":"build-2784847793"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"\n Background:<\/jats:title>\n Mucormycosis is an angioinvasive mucorales fungal infection. Cutaneous type formed 10.5% of cases in India in precovid-19 era. Glucocorticoid-induced immunosuppression and hyperglycemia, reusable oxygen humidifiers in COVID-19 therapy, and preexisting uncontrolled diabetes mellitus contribute to post-COVID-19 mucormycosis. However, for post-COVID-19 cutaneous mucormycosis, sufficient data is not available.<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n To study factors related to post-COVID-19 cutaneous mucormycosis.<\/jats:p>\n <\/jats:sec>\n \n Methodology:<\/jats:title>\n Clinical and investigation details of six patients admitted in tertiary center with post-COVID-19 cutaneous mucormycosis.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Among six patients, three were males and three females; all in 45\u201360 years age group from districts under tertiary center. Site of eschar was face (four) and lips (two). All six were positive for COVID-19 10\u201312 days prior to admission for mucormycosis. All had intravenous steroids and supportive humidified oxygen therapy for minimum 1 week under COVID-19 treatment. They presented to emergency with ophthalmic\/ENT complaints; subsequently, they developed cutaneous manifestations within 2\u20133 days. All six had diabetes mellitus, with above 400 mg\/dL sugar levels at admission.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n This study's findings correlated with various studies across the country and elsewhere. Preexisting diabetes mellitus and steroid therapy for COVID-19 increase the risk of mucormycosis. Caution for early diagnosis, maintaining blood glucose levels, and judicious use of steroids for treatment of COVID-19 are indicated.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijd.ijd_781_21","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T17:20:18Z","timestamp":1724952018000},"page":"206","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Secondary Cutaneous Mucormycosis Post-COVID-19"],"prefix":"10.4103","volume":"67","author":[{"given":"B","family":"Abhirami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhat","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmendra Kumar","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyendra Prasad","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-44-20240829","doi-asserted-by":"crossref","first-page":"102146","DOI":"10.1016\/j.dsx.2021.05.019","article-title":"Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"R2-44-20240829","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/cid\/cir866","article-title":"Epidemiology and clinical manifestations of mucormycosis","volume":"54","author":"Petrikkos","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R3-44-20240829","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1590\/abd1806-4841.20176614","article-title":"Cutaneous mucormycosis","volume":"92","author":"Castrej\u00f3n-P\u00e9rez","year":"2017","journal-title":"An Bras Dermatol"},{"key":"R4-44-20240829","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ajd.13508","article-title":"Mucormycosis with cutaneous involvement. A retrospective study of 115 cases at a tertiary care hospital in Mexico","volume":"62","author":"Bonifaz","year":"2021","journal-title":"Australas J Dermatol"},{"key":"R5-44-20240829","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/hpm.3311","article-title":"The risk of cutaneous mucormycosis associated with COVID 19: A perspective from Pakistan","volume":"37","author":"Asri","year":"2022","journal-title":"Int J Health Plann Manage"},{"key":"R6-44-20240829","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/jof6040265","article-title":"Epidemiology and diagnosis of mucormycosis: An update","volume":"6","author":"Skiada","year":"2020","journal-title":"J Fungi"},{"key":"R7-44-20240829","first-page":"1","article-title":"Mucormycosis: A black fungus- post covid complications","volume":"3","author":"KR Kumar","year":"2021","journal-title":"J Regan Biol Med"},{"key":"R8-44-20240829","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s10384-021-00845-5","article-title":"Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations","volume":"65","author":"Bayram","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"R9-44-20240829","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11046-021-00528-2","article-title":"Coronavirus disease (Covid-19) associated mucormycosis (CAM): Case report and systematic review of literature","volume":"186","author":"Garg","year":"2021","journal-title":"Mycopathologia"},{"key":"R10-44-20240829","doi-asserted-by":"crossref","first-page":"101125","DOI":"10.1016\/j.mycmed.2021.101125","article-title":"Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient-Case report and review of literature","volume":"31","author":"Khatri","year":"2021","journal-title":"J Mycol Med"},{"key":"R11-44-20240829","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1017\/S0022215121000992","article-title":"Post coronavirus disease mucormycosis: A deadly addition to the pandemic spectrum","volume":"135","author":"Sharma","year":"2021","journal-title":"J Laryngol Otol"},{"key":"R12-44-20240829","first-page":"140537","article-title":"Intercepting the deadly trinity of mucormycosis, diabetes and COVID-19 in India","volume":"8","author":"Banerjee","year":"2021","journal-title":"J Postgrad Med"},{"key":"R13-44-20240829","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalised patients with COVID-19","volume":"384","author":"Horby","year":"2021","journal-title":"N Engl J Med"},{"key":"R14-44-20240829","first-page":"E161","article-title":"Humidifiers for oxygen therapy: What risk for reusable and disposable devices?","volume":"58","author":"La Fauci","year":"2017","journal-title":"J Prev Med Hyg"},{"key":"R15-44-20240829","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdcr.2021.06.012","article-title":"Cutaneous mucormycosis following COVID-19 vaccination in a patient with bullous pemphigoid","volume":"15","author":"Shah","year":"2021","journal-title":"JAAD Case Rep"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_781_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:15:19Z","timestamp":1787771719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_781_21"}},"subtitle":["Case Series from a Tertiary Center"],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_781_21","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}